Cart
sales@molnova.com
AXL-IN-13
CAS No. 2376928-82-2
AXL-IN-13( —— )
Catalog No. M36512 CAS No. 2376928-82-2
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 181 | In Stock |
|
| 10MG | 266 | In Stock |
|
| 25MG | 456 | In Stock |
|
| 50MG | 639 | In Stock |
|
| 100MG | 928 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1851 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAXL-IN-13
-
NoteResearch use only, not for human use.
-
Brief DescriptionAXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM.
-
DescriptionAXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.
-
In VitroWestern Blot Analysis Cell Line:MDA-MB-231 cells Concentration:0, 0.11, 0.33, 1, 3 μM.Incubation Time:3 daysResult:Restored the protein levels of E-cadherin and N-cadherin to control levels.Cell Migration Assay Cell Line:MDA-MB-231 cell Concentration:0, 0.11, 0.33, 1, 3 μM.Incubation Time:24 h Result:Inhibited cell migration at 1 and 3 μM.Inhibited the invasion of MDA-MB-231 cells by 22.6, 34.8, 56.5, and 70.4% at the concentrations of 0.11, 0.33, 1.0, and 3.0 μM, respectively.
-
In VivoAnimal Model:Xenograft model derived from highly metastatic 4T1 cells.Dosage:50 or 100 mg/kg Administration:Oral administration (p.o.)Result:Suppressed 4T1 tumor growth with a tumor growth inhibition (TGI) of 78.0 and 95.9% at 50 and 100 mg/kg, respectively. Inhibited the phosphorylation of AXL. Showed that liver is one of the most common sites of breast cancer metastasis.Animal Model:Rats Dosage:5 mg/kg (i.v.), 25 mg/kg (p.o.) Administration:Intravenous injection (i.v.), oral administration (p.o.)Result:Pharmacokinetic parameters of AXL-IN-13 (Compound 6li).
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFLT
-
RecptorFLT | PDGFR | TGF-beta/Smad | TAM Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2376928-82-2
-
Formula Weight632.72
-
Molecular FormulaC34H41FN6O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (158.05 mM; Ultrasonic )
-
SMILESO(C=1C2=C(C=C(OCCCN3CCOCC3)C(OC)=C2)N=CC1)C4=C(F)C=C(NC=5C(C(NC6CCCCC6)=O)=CN(C)N5)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chan S, et al. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors. J Med Chem. 2022 Nov 24;65(22):15374-15390. ?
molnova catalog
related products
-
HM43239 B
HM43239 is an orally active and selective FLT3 inhibitor with IC 50 s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively.
-
Gilteritinib hemifum...
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML.
-
Pacritinib
Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.
